Conceptio › Archive › HAL (France)
HAL (France)open access

Treatment of epistaxis in Osler-Weber-Rendu disease by bevacizumab nasal spray. The EROSB study: Determining the effective dose

L. Vincent et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
Epistaxis Osler-Weber-Rendu disease Bevacizumab, 1, 0
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 1038968
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.